Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
ISIN : ARDEUT111192
Share Class Description:
BUE:LLY: CedearDescription
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 2.34 | |||||
| Debt-to-EBITDA | 2.94 | |||||
| Interest Coverage | 22.68 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.89 | |||||
| Beneish M-Score | -1.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12 | |||||
| 3-Year EBITDA Growth Rate | -1 | |||||
| 3-Year EPS without NRI Growth Rate | 0.8 | |||||
| 3-Year Book Growth Rate | 24.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 50.68 | |||||
| Future 3-5Y Total Revenue Growth Rate | 17.33 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.84 | |||||
| 9-Day RSI | 29.43 | |||||
| 14-Day RSI | 30.72 | |||||
| 6-1 Month Momentum % | -78.76 | |||||
| 12-1 Month Momentum % | -24.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | |||||
| Quick Ratio | 0.73 | |||||
| Cash Ratio | 0.11 | |||||
| Days Inventory | 250.76 | |||||
| Days Sales Outstanding | 83.85 | |||||
| Days Payable | 118.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.12 | |||||
| Dividend Payout Ratio | 0.02 | |||||
| 3-Year Dividend Growth Rate | 15.2 | |||||
| Forward Dividend Yield % | 0.57 | |||||
| 5-Year Yield-on-Cost % | 2.19 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 0.1 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.25 | |||||
| Operating Margin % | 32.29 | |||||
| Net Margin % | 15.36 | |||||
| FCF Margin % | -12.2 | |||||
| ROE % | 47.73 | |||||
| ROA % | 9.38 | |||||
| ROIC % | 21.84 | |||||
| ROC (Joel Greenblatt) % | 61.86 | |||||
| ROCE % | 19.77 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 127.74 | |||||
| Forward PE Ratio | 0.32 | |||||
| PE Ratio without NRI | 82.41 | |||||
| Shiller PE Ratio | 143.74 | |||||
| PEG Ratio | 7.7 | |||||
| PS Ratio | 19.21 | |||||
| PB Ratio | 64.01 | |||||
| Price-to-Operating-Cash-Flow | 154.4 | |||||
| EV-to-EBIT | 101.25 | |||||
| EV-to-Forward-EBIT | 52.82 | |||||
| EV-to-EBITDA | 83.2 | |||||
| EV-to-Forward-EBITDA | 48.15 | |||||
| EV-to-Revenue | 20.89 | |||||
| EV-to-Forward-Revenue | 17.26 | |||||
| EV-to-FCF | -226.16 | |||||
| Price-to-Projected-FCF | 12.45 | |||||
| Price-to-Median-PS-Value | 3.59 | |||||
| Price-to-Peter-Lynch-Fair-Value | 7.69 | |||||
| Earnings Yield (Greenblatt) % | 0.99 | |||||
| FCF Yield % | -0.46 | |||||
| Forward Rate of Return (Yacktman) % | 11.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ARS) | 10,070,464.581 | ||
| EPS (TTM) (ARS) | 6295.779 | ||
| Beta | 0 | ||
| Volatility % | 119.5 | ||
| 14-Day RSI | 30.72 | ||
| 14-Day ATR (ARS) | 574.219228 | ||
| 20-Day SMA (ARS) | 14579.5 | ||
| 12-1 Month Momentum % | -24.16 | ||
| 52-Week Range (ARS) | 13005.5 - 105913 | ||
| Shares Outstanding (Mil) | 237.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eli Lilly and Co Stock Events
| Event | Date | Price(ARS) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(BUE:LLY)'s stock price today?
The current price of BUE:LLY is ARS13828.50. The 52 week high of BUE:LLY is ARS105913.00 and 52 week low is ARS13005.50.
When is next earnings date of Eli Lilly and Co(BUE:LLY)?
The next earnings date of Eli Lilly and Co(BUE:LLY) is 2024-04-30.
Does Eli Lilly and Co(BUE:LLY) pay dividends? If so, how much?
The Dividend Yield %  of Eli Lilly and Co(BUE:LLY) is 1.12% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(BUE:LLY) was 1.96. The lowest was 0.02. And the median was 0.56. The  Forward Dividend Yield % of Eli Lilly and Co(BUE:LLY) is 0.57%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers